---
title: "Nephrocare Health Services Ltd (NEPHROPLUS) — Share Price, Financials & Analysis"
symbol: "NEPHROPLUS"
company: "Nephrocare Health Services Ltd"
canonical: "https://tapetide.com/stocks/NEPHROPLUS"
isin: "INE428V01029"
nse_symbol: "NEPHROPLUS"
bse_code: "544647"
sector: "Healthcare Services"
industry: "Healthcare Service Provider"
market_cap_cr: 7488.93
generated_at: "2026-09-13T18:50:00.785Z"
---

# Nephrocare Health Services Ltd (NEPHROPLUS)

Canonical page: https://tapetide.com/stocks/NEPHROPLUS

## Company

- **NSE Symbol:** NEPHROPLUS
- **BSE Code:** 544647
- **ISIN:** INE428V01029
- **Sector:** Healthcare Services
- **Industry:** Healthcare Service Provider
- **Macro Sector:** Healthcare
- **Stock Type:** EQUITY
- **Listed Since:** 2025-12-17
- **Face Value:** ₹2
- **F&O Eligible:** No
- **Website:** nephroplus.com

## About

Incorporated in 2010, Nephrocare Health Services Ltd. provides end-to-end dialysis care through a wide network of clinics across India and select international markets.[1]

## Latest Price

- **Price:** ₹765.35
- **Change:** +18.1 (+2.42%)
- **Open:** ₹747.25
- **Day High:** ₹781.5
- **Day Low:** ₹734.05
- **Previous Close:** ₹747.25
- **Volume:** 337264
- **As Of:** 2026-09-11T10:23:58+00:00

## Key Fundamentals

Observed at 2026-09-11T04:53:24.440905Z.

- **Market Cap:** ₹7488.93 Cr
- **Classification:** Microcap
- **P/E (reported):** 88.3
- **P/E (TTM):** 182.66
- **EPS (TTM):** ₹4.19
- **Book Value:** ₹111.03
- **Price to Book:** 6.73
- **Dividend Yield:** 0%
- **ROE:** 6.88%
- **ROCE:** 13.46%
- **Debt to Equity:** 0.07
- **Revenue (yearly):** ₹1023.4 Cr
- **Net Income:** ₹76.8 Cr
- **EBITDA:** ₹251.5 Cr
- **52-Week High:** ₹769.75
- **52-Week Low:** ₹446
- **RSI (14):** 65.01

## Key Insights

### Strengths

- Company has reduced debt.
- Company is almost debt free.
- Company has delivered good profit growth of 162% CAGR over last 5 years

### Weaknesses

- Stock is trading at 6.88 times its book value
- Though the company is reporting repeated profits, it is not paying out dividend
- Company has a low return on equity of 10.2% over last 3 years.
- Company's cost of borrowing seems high

## Growth Rates

| Metric | QoQ | 1Y | 3Y | 5Y |
| --- | --- | --- | --- | --- |
| cash flow growth | — | 71.84% | 221.78% | — |
| ebitda margin growth | 9% | 4.64% | 29.04% | 213.39% |
| net income growth | 5.26% | 14.46% | 103% | 162% |
| revenue growth | 4.33% | 32.93% | 32% | 28% |
| roce | 18.79% | -11.39% | 42.13% | 7.23% |
| roe | 5.27% | -40.12% | 8.95% | -227.64% |

## Financial Statements

### Quarterly Results

All figures in ₹ crore unless the row name says otherwise.

| Item | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Sales | 197 | 219 | 228 | 246 | 260 | 266 | 282 |
| Expenses | 153 | 168 | 180 | 182 | 199 | 215 | 221 |
| Operating Profit | 44 | 51 | 48 | 64 | 61 | 51 | 60 |
| OPM % | 22 | 23 | 21 | 26 | 23 | 19 | 21 |
| Other Income | 5 | 4 | 7 | 4 | 3 | 12 | 7 |
| Interest | 5 | 6 | 6 | 45 | 6 | 3 | 2 |
| Depreciation | 18 | 19 | 20 | 23 | 22 | 26 | 25 |
| Profit before tax | 26 | 30 | 29 | -1 | 36 | 33 | 41 |
| Tax % | 24 | 17 | 17 | 1427 | 11 | 9 | 22 |
| Net Profit | 20 | 25 | 24 | -9 | 32 | 30 | 32 |
| EPS in Rs | 96.5 | 119.3 | 13.1 | -5.24 | 3.21 | 3.03 | 3.19 |

### Profit & Loss

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Sales | 286 | 318 | 437 | 566 | 756 | 999 | 1053 |
| Expenses | 248 | 302 | 389 | 465 | 589 | 774 | 817 |
| Operating Profit | 37 | 16 | 49 | 101 | 167 | 225 | 236 |
| OPM % | 13 | 5 | 11 | 18 | 22 | 23 | 22 |
| Other Income | 5 | 10 | 6 | 8 | 14 | 23 | 26 |
| Interest | 7 | 10 | 16 | 20 | 21 | 60 | 56 |
| Depreciation | 34 | 42 | 47 | 56 | 72 | 91 | 96 |
| Profit before tax | 1 | -27 | -9 | 33 | 87 | 97 | 110 |
| Tax % | 31 | -21 | 37 | -6 | 23 | 21 | — |
| Net Profit | 1 | -21 | -12 | 35 | 67 | 77 | 85 |
| EPS in Rs | 3.4 | -106.93 | -58.69 | 169.82 | 321.87 | 7.66 | 4.19 |
| Dividend Payout % | 0 | 0 | 0 | 0 | 0 | 0 | — |

### Balance Sheet

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- |
| Equity Capital | 2 | 2 | 2 | 2 | 2 | 20 |
| Reserves | 245 | 391 | 384 | 409 | 579 | 1096 |
| Borrowings | 140 | 119 | 200 | 271 | 261 | 80 |
| Other Liabilities | 42 | 59 | 81 | 124 | 153 | 271 |
| Total Liabilities | 428 | 571 | 666 | 806 | 994 | 1467 |
| Fixed Assets | 192 | 205 | 239 | 356 | 396 | 517 |
| CWIP | 2 | 43 | 34 | 1 | 6 | 6 |
| Investments | 0 | 0 | 0 | 0 | 51 | 178 |
| Other Assets | 234 | 322 | 393 | 449 | 542 | 767 |
| Total Assets | 428 | 571 | 666 | 806 | 994 | 1467 |

### Cash Flow

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- |
| Cash from Operating Activity | 32 | 14 | 11 | 72 | 135 | 233 |
| Cash from Investing Activity | -62 | -130 | -76 | -52 | -125 | -392 |
| Cash from Financing Activity | 36 | 121 | 60 | 27 | 54 | 157 |
| Net Cash Flow | 5 | 6 | -4 | 47 | 65 | -2 |
| Free Cash Flow | -29 | -64 | -62 | -8 | 35 | 113 |
| CFO/OP | 49 | 119 | 14 | 80 | 82 | 116 |

### Ratios

| Item | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- |
| Debtor Days | 101 | 123 | 132 | 131 | 129 | 116 |
| Inventory Days | 65 | 50 | 67 | — | — | — |
| Days Payable | 56 | 70 | 63 | — | — | — |
| Cash Conversion Cycle | 110 | 103 | 137 | 131 | 129 | 116 |
| Working Capital Days | 26 | 55 | 19 | 56 | 27 | 42 |
| ROCE % | — | -4 | 1 | 8 | 14 | 15 |

## Shareholding Pattern

### Quarterly

| Category | Dec 2025 | Mar 2026 | Jun 2026 |
| --- | --- | --- | --- |
| Promoters | 63.85% | 63.85% | 63.85% |
| FIIs | 9.3% | 9.94% | 8.78% |
| DIIs | 8.1% | 8.65% | 9.05% |
| Government | 0% | 0% | 0% |
| Public | 5.92% | 5.08% | 5.7% |
| Others | 12.82% | 12.48% | 12.62% |
| No. of Shareholders | 36 | 43409 | 44091 |

## Technical Indicators

Derived from daily closing prices and recomputed each trading session; values move with the market.

- **Overall Signal:** Strong Buy
- **Buy / Neutral / Sell:** 11 / 5 / 3

### Moving Averages — summary: **Strong Buy**

| Indicator | Value | Signal |
| --- | --- | --- |
| SMA (10) | 717.01 | Buy |
| EMA (10) | 725.97 | Buy |
| SMA (20) | 703.96 | Buy |
| EMA (20) | 711.32 | Buy |
| SMA (50) | 684.25 | Buy |
| EMA (50) | 690.25 | Buy |
| SMA (100) | 658.23 | Buy |
| EMA (100) | 658.35 | Buy |
| SMA (200) | — | Neutral |
| EMA (200) | — | Neutral |

### Oscillators — summary: **Neutral**

| Indicator | Value | Signal |
| --- | --- | --- |
| RSI (14) | 68.67 | Neutral |
| MACD (12,26,9) | 15.82 | Buy |
| Stochastic (14,3,3) | 82.17 | Sell |
| ADX (14) | 27.74 | Buy |
| Williams %R (14) | -14.36 | Sell |
| ATR (14) | 27.59 | High Volatility |
| ROC (12) | 10.34 | Buy |
| Stoch RSI (14) | 100 | Sell |
| UO (7,14,28) | 57.14 | Neutral |

## Analyst Ratings

| Recommendation | Analysts | Share |
| --- | --- | --- |
| Buy | 3 | 100% |
| Hold | 0 | 0% |
| Sell | 0 | 0% |

Based on 3 analyst ratings, observed at 2026-09-11T04:53:25.496913+00:00.

## Filings & Documents

### Exchange Filings & Announcements

| Date | Document |
| --- | --- |
| 2026-09-03 | [Disclosure Under Regulation 30 Of The SEBI Listing Regulations - Grant Of Esops Under The Nephroplus Employee Stock Option Scheme 2026.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=1dc8d037-13f5-4a91-b5e0-52f57b2ef49e.pdf) |
| 2026-09-01 | [Announcement under Regulation 30 (LODR)-Acquisition](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=15aebda6-e1bc-460e-b047-a4643ef63335.pdf) |
| 2026-08-31 | [Disclosure Under Regulation 30 Of SEBI Listing Regulations](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=0cd59b3f-f4f4-4079-8644-5367398209de.pdf) |
| 2026-08-17 | [Announcement under Regulation 30 (LODR)-Memorandum of Understanding /Agreements](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=098af1c6-5fe2-4e35-9dfb-b6acdcc7d5a9.pdf) |
| 2026-08-13 | [Announcement under Regulation 30 (LODR)-Memorandum of Understanding /Agreements](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=356c8200-cca2-4da0-8499-d6eb64e97e17.pdf) |
| 2026-08-13 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=21b22af3-db0f-4e58-bfbd-e00b6119565c.pdf) |
| 2026-08-13 | [Shareholder Meeting / Postal Ballot-Scrutinizers Report](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=4fb878c1-c3a7-419f-8154-897fe62a27ac.pdf) |
| 2026-08-12 | [Shareholder Meeting / Postal Ballot-Outcome of AGM](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=9d1cd672-ac24-4d4c-b64a-5a46b14d345b.pdf) |
| 2026-08-12 | [Announcement under Regulation 30 (LODR)-Updates on Acquisition](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=cbdfde35-21c8-43c4-9634-c1fa4e9a4266.pdf) |
| 2026-08-11 | [Announcement under Regulation 30 (LODR)-Press Release / Media Release](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=a65f71c2-2d59-414d-8ddb-4f94b15e7a60.pdf) |

### Earnings Call Transcripts

| Date | Document |
| --- | --- |
| 2026-08-19 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=625565e6-770d-4404-bdda-42664a68f614.pdf) |
| 2026-05-27 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=5b792f3c-c313-4aaa-8204-72572d2ba5d5.pdf) |
| 2026-02-18 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=90aeb06c-1feb-4443-96cf-95c0bbdcb74b.pdf) |

### Earnings Call Recordings

| Date | Document |
| --- | --- |
| 2026-08-12 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=c487b8d8-a41a-41a8-97f4-316e786195be.pdf) |
| 2026-05-20 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=6c25238f-3f3c-4fda-a002-102f2d884acd.pdf) |
| 2026-02-11 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=1ced5967-1112-484f-aad2-fe9a7c372bdb.pdf) |

### Results & Financial Statements

| Date | Document |
| --- | --- |
| 2026-08-11 | [Financial Results For The Quarter Ended June 30 2026](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=50fc2afc-c153-444a-9751-1b12aba2a4bd.pdf) |

### Investor Presentations

| Date | Document |
| --- | --- |
| 2026-08-11 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=673e16da-21dc-430c-aa81-56e74b06cb0d.pdf) |
| 2026-05-19 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=70dcb161-0885-4677-86d8-acd05673bfc7.pdf) |
| 2026-02-10 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=39571fa0-ff44-40db-991e-c71a528d5948.pdf) |

### Other Documents

| Date | Document |
| --- | --- |
| 3 Apr - Mr. Prashant Goenka, CFO, also designated Chief Risk Officer effective April 3, 2026. | [Announcement under Regulation 30 (LODR)-Change in Management 3 Apr - Mr. Prashant Goenka, CFO, also designated Chief Risk Officer effective April 3, 2026.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/5a80a471-7e79-4a60-8d3f-e4b462b40e2f.pdf) |
| 25 Mar - Trading window closed from April 1, 2026 until 48 hours after audited results for quarter/year ended March 31, 2026. | [Closure of Trading Window 25 Mar - Trading window closed from April 1, 2026 until 48 hours after audited results for quarter/year ended March 31, 2026.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/369710c8-4ff7-43f9-8b15-7542490a2acc.pdf) |
| 2 Apr - Company filed writ petition on April 2, 2026 challenging GST demand of ₹2.51 crore and recovery proceedings. | [Announcement Under Regulation 30 (LODR)- Disclosure Of Litigation Filed By The Company 2 Apr - Company filed writ petition on April 2, 2026 challenging GST demand of ₹2.51 crore and recovery proceedings.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/3f875371-ec2a-4a1e-bf90-56d3d6c9bfd8.pdf) |
| 18 Feb - Attending IIFL investor conference in Mumbai on 24 Feb 2026, 1:00 PM; public information only. | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 18 Feb - Attending IIFL investor conference in Mumbai on 24 Feb 2026, 1:00 PM; public information only.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/810fdfa7-04d6-4583-9a57-fd946314c711.pdf) |
| 12 Feb - Subsidiary acquired Laurel, Batangas dialysis center assets for PHP 49,400,000 under ATA dated Feb 12, 2026. | [Announcement under Regulation 30 (LODR)-Memorandum of Understanding /Agreements 12 Feb - Subsidiary acquired Laurel, Batangas dialysis center assets for PHP 49,400,000 under ATA dated Feb 12, 2026.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/57d2cea1-4a37-41bc-8acb-abb930d6ab55.pdf) |
| 12 Feb - Crisil monitoring report: Rs3,534.05m IPO; Rs904.99m utilized; Rs2,629.06m unutilized as of Dec 31, 2025. | [Announcement under Regulation 30 (LODR)-Monitoring Agency Report 12 Feb - Crisil monitoring report: Rs3,534.05m IPO; Rs904.99m utilized; Rs2,629.06m unutilized as of Dec 31, 2025.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/c620ca7f-cfb7-4bae-806f-8568d5c4ab64.pdf) |
| 10 Apr - Regulation 74(5) certificate filed for quarter ended March 31, 2026. | [Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 10 Apr - Regulation 74(5) certificate filed for quarter ended March 31, 2026.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/c5d809f9-a233-4d4e-9598-3a6c5e495ab8.pdf) |
| — | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 4 May](https://www.bseindia.com/xml-data/corpfiling/AttachHis/f531a00b-95fe-489e-b05a-d022b4b53be5.pdf) |
| — | [Board Meeting Intimation for Intimation Of Board Meeting For Considering Audited Financial Results Of The Company. 4 May](https://www.bseindia.com/xml-data/corpfiling/AttachHis/9aa6fd6e-a01a-43cd-9181-d9925d0a34fc.pdf) |
| — | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 4 May](https://www.bseindia.com/xml-data/corpfiling/AttachLive/f531a00b-95fe-489e-b05a-d022b4b53be5.pdf) |

### Earnings Call Documents

| Date | Document |
| --- | --- |
| May 2026 | [Concall - May 2026](https://www.bseindia.com/xml-data/corpfiling/AttachHis/5b792f3c-c313-4aaa-8204-72572d2ba5d5.pdf) |
| May 2026 | [Concall - May 2026](https://www.bseindia.com/xml-data/corpfiling/AttachLive/5b792f3c-c313-4aaa-8204-72572d2ba5d5.pdf) |
| May 2026 | [Concall - May 2026](https://www.bseindia.com/xml-data/corpfiling/AttachHis/70dcb161-0885-4677-86d8-acd05673bfc7.pdf) |
| May 2026 | [Concall - May 2026](https://www.bseindia.com/xml-data/corpfiling/AttachLive/70dcb161-0885-4677-86d8-acd05673bfc7.pdf) |

---

Provenance differs by section. Financial statements, shareholding and filings are as reported in company disclosures to NSE/BSE/SEBI. Price, volume and 52-week levels are exchange market data. Technical indicators are computed by Tapetide from daily closing prices. The Tapetide Score is Tapetide's own analysis. Analyst ratings are third-party estimates, not company statements. All figures are for research and information only and are not investment advice. Generated 2026-09-13T18:50:00.785Z.